Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Dan T Vogl, Shebli Atrash, Sarah A Holstein, Omar Nadeem, Don M Benson, Jr, Maria Chaudhry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu, Sabrina Christine Collins, Xavier Parot, Jonathan L Kaufman

Blood blood.2024026124.

https://doi.org/10.1182/blood.2024026124

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Blood (2024) 144 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2024-206608

Published: 2024

Journal Articles

P2RX5-Directed CAR-T Cells for Genotype-Guided Treatment of Lymphoid and Plasma Cell Malignancies in Patients of African Ancestry

Zhiwei Ang, Castro Annette, Carolin Schimdt, Katharina Hayer, Zainul S. Hasanali, Manuel Torres-Diz, Patricia King Sainos, Christopher Kwok, Kayla Ji, Patrick Krohl, Justyn Fine, Priyanka Sehgal, Dan Martinez, Dan T. Vogl, Jamie B. Spangler, David Allman, Andrei Thomas-Tikhonenko

Blood (2024) 144 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2024-208126

Published: 2024

Journal Articles

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Rahul Banerjee, Amber R. Fritz, Othman S. Akhtar, Ciara Louise Freeman, Andrew J. Cowan, Nina Shah, Heather J. Landau, Shaji Kumar, Dan T. Vogl, Yvonne A. Efebera, Philip L. McCarthy, David H. Vesole, Adam Mendizabal, Amrita Y Krishnan, George Somlo, Edward A. Stadtmauer, Marcelo C. Pasquini

Blood (2024) 144 (Supplement 1): 81.

https://doi.org/10.1182/blood-2024-199615

Published: 2024

Journal Articles

Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Dan T. Vogl, Yulia Nefedova, E. Paul Wileyto, Chau Nguyen, Cynthia Diaczynsky, Inna Strakovsky, Eva Bondesson, Helen Tuvesson, Erik Vahtola, Adam D. Cohen, Sandra Susanibar-Adaniya, Adam Waxman, Shivani Kapur, Alfred L. Garfall, Edward A. Stadtmauer

Blood (2024) 144 (Supplement 1): 7060.

https://doi.org/10.1182/blood-2024-204155

Published: 2024

Journal Articles

A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Blood (2024) 144 (Supplement 1): 3381.1.

https://doi.org/10.1182/blood-2024-199411

Published: 2024

Journal Articles

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2024-198119

Published: 2024

Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Luca Paruzzo, Khashayar Eshaghi, Guido Ghilardi, Abigail Doucette, Adam Waxman, Adam D. Cohen, Dan T. Vogl, Shivani Kapur, Eugenio Fardella, Alberto Carturan, Luke Maillie, Sofia Kaparis, Jalpa A. Doshi, Alfred L. Garfall, Edward A. Stadtmauer, Carmen E Guerra, Sandra Susanibar-Adaniya, Marco Ruella

Blood (2024) 144 (Supplement 1): 3779.

https://doi.org/10.1182/blood-2024-206544

Published: 2024

Journal Articles

Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors

Zainul S. Hasanali, Alfred L. Garfall, Dan T. Vogl, Sandra Susanibar-Adaniya, Adam D. Cohen, Edward A. Stadtmauer, Shivani Kapur, Adam Waxman, David Allman

Blood (2024) 144 (Supplement 1): 3266.

https://doi.org/10.1182/blood-2024-209100

Published: 2024

Journal Articles

Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study

Adam D. Cohen, Sandra Susanibar-Adaniya, Oksana De Mesa, Alfred L. Garfall, Dan T. Vogl, Adam Waxman, Shivani Kapur, E Paul Wileyto, Anjana Nair, Zainul S. Hasanali, Lauren Karpf, Edward A. Stadtmauer

Blood (2024) 144 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2024-203635

Published: 2024

Journal Articles

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Blood (2024) 143 (2): 139–151.

https://doi.org/10.1182/blood.2022018658

Published: 2024

Includes: Supplemental data

Journal Articles

A Randomized Controlled Trial of a Financial Navigation Program for Patients with Multiple Myeloma

Mia Djulbegovic, Meredith Doherty, Katie Fanslau, Kan Chen, Sarah Girgis, Pearl Joslyn, Shawn Carney, Joyce Mitchell, Abbie Etzweiler, Dan T. Vogl, Adam D. Cohen, Alfred L. Garfall, Adam Waxman, Sandra Susanibar-Adaniya, Zachary AK Frosch, Qi Long, Karen Glanz, Edward A. Stadtmauer

Blood (2023) 142 (Supplement 1): 909.

https://doi.org/10.1182/blood-2023-174451

Published: 2023

Journal Articles

Safety and Efficacy of Teclistamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series

Margaret Stalker, Alfred L. Garfall, Adam D. Cohen, Dan T. Vogl, Sandra Susanibar-Adaniya, Mia Djulbegovic, Edward A. Stadtmauer, Oxana Megherea, Adam Waxman

Blood (2023) 142 (Supplement 1): 2035.

https://doi.org/10.1182/blood-2023-189277

Published: 2023

Journal Articles

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Adam D. Cohen, Wei-Ting Hwang, Sandra Susanibar-Adaniya, Dan T. Vogl, Alfred L. Garfall, Adam Waxman, Danielle Zubka, Chau Nguyen, Cynthia Diaczynsky, Marco Ruella, Michael C. Milone, Edward A. Stadtmauer

Blood (2023) 142 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2023-187409

Published: 2023

Journal Articles

A Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Beatrice Razzo, Connor Grady, Sandra Susanibar-Adaniya, Adam Waxman, Dan T. Vogl, Adam D. Cohen, Edward A. Stadtmauer, Wei-Ting Hwang, Alfred L. Garfall

Blood (2023) 142 (Supplement 1): 3394.

https://doi.org/10.1182/blood-2023-177735

Published: 2023

Journal Articles

Modakafusp Alfa Demonstrates Type I Interferon-Mediated Innate and Adaptive Immune Enhancement in a Phase 1/2 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Gurpanna Saggu, Min Young Lee, Faith Dunbar, Reshma Singh, Kris Sachsenmeier, Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Jonathan L. Kaufman, Adarsh Joshi, Kaveri Suryanarayan, Sabrina Collins

Blood (2023) 142 (Supplement 1): 3316.

https://doi.org/10.1182/blood-2023-177909

Published: 2023

Journal Articles

Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don M. Benson, Jr., Kaveri Suryanarayan, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman

Blood (2022) 140 (Supplement 1): 1357–1359.

https://doi.org/10.1182/blood-2022-162253

Published: 2022

Journal Articles

Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Brian Hoeynck, Wei-Ting Hwang, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer, Adam D Cohen

Blood (2022) 140 (Supplement 1): 10081–10083.

https://doi.org/10.1182/blood-2022-165650

Published: 2022

Journal Articles

Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

Adam D Cohen, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Oksana De Mesa, Elizabeth Kane, Charles Nichols, Beatrice Razzo, Edward A. Stadtmauer

Blood (2022) 140 (Supplement 1): 12628–12629.

https://doi.org/10.1182/blood-2022-165526

Published: 2022

Journal Articles

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Blood (2022) 139 (9): 1289–1301.

https://doi.org/10.1182/blood.2020008493

Published: 2022

Includes: Supplemental data

NARROW

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

P2RX5-Directed CAR-T Cells for Genotype-Guided Treatment of Lymphoid and Plasma Cell Malignancies in Patients of African Ancestry

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors

Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

A Randomized Controlled Trial of a Financial Navigation Program for Patients with Multiple Myeloma

Safety and Efficacy of Teclistamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

A Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Modakafusp Alfa Demonstrates Type I Interferon-Mediated Innate and Adaptive Immune Enhancement in a Phase 1/2 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only